Seroatlas · Human Serome Atlas

MIR17HG

Putative microRNA 17 host gene protein

Also known as: MIRH1_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q75NE6
Gene: MIR17HG
Canonical length: 70 aa

OverviewNCBI Gene

No narrative summary is available for MIR17HG in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

70 residues, UniProt reviewed canonical sequence.

>Q75NE6|MIR17HG
     1  MFCHVDVKIS SKRYTWTKLP LNVPKLVLIY LQSHFVLFFF SMCQSIWERP AIGRATTSSA
    61  SWMVGYDCLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MIR17HG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.56

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MIR17HG.

Disease | AllUniProt

Conditions MIR17HG is implicated in, by any mechanism.

Feingold syndrome 2 (FGLDS2) MIM:614326

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 28 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Feingold syndrome type 2

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

membrane

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MIR17HG as an antibody target. Whether an autoantibody or antibody against MIR17HG could matter depends on whether native MIR17HG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MIR17HG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MIR17HG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...